Filtered By:
Management: Marketing
This page shows you your search results in order of date.
Order by Relevance | Date
Total 56 results found since Jan 2013.
Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
DUBLIN, Aug. 31, 2023 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that its Specialty Generics segment, operating as SpecGx LLC, received approval on August 25, ... Biopharmaceuticals, Generics, FDA Mallinckrodt, SpecGx, lisdexamfetamine, ADHD
Source: HSMN NewsFeed - August 31, 2023 Category: Pharmaceuticals Source Type: news
News Exclusive | DEA Pressed ADHD-Drug Makers About Impact of Telehealth Firms on Surging Demand
The Drug Enforcement Administration told makers of medication for attention-deficit hyperactivity disorder that it was concerned that “aggressive marketing practices” by companies including telehealth providers could be driving excessive prescriptions, according to a letter from the agency. While…#dea #cerebralinc #doneglobalinc
Source: Reuters: Health - December 31, 2022 Category: Consumer Health News Source Type: news
Supernus Announces FDA Approval of Qelbree(R) for the Treatment of ADHD in Adults
First novel, nonstimulant option for adults with ADHD in 20 years
ADHD affects an estimated 10 million adults in the U.S.
ROCKVILLE, Md., May 2, 2022 -- (Healthcare Sales & Marketing Network) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a bioph... Biopharmaceuticals, Neurology, FDA Supernus Pharmaceuticals, viloxazine, Qelbree, ADHD
Source: HSMN NewsFeed - May 2, 2022 Category: Pharmaceuticals Source Type: news
Corium Launches Innovative ADHD Treatment AZSTARYS(TM) (serdexmethylphenidate and dexmethylphenidate) in the U.S. for Patients Age 6 Years and Older
AZSTARYS is the First and Only Product Containing Prodrug of Dexmethylphenidate
Unique formulation provides rapid and extended duration symptom control
BOSTON, July 21, 2021 -- (Healthcare Sales & Marketing Network) -- Corium, Inc., a commercial-sta... Biopharmaceutical, Neurology, Product Launch Corium Inc, AZSTARYS, ADHD
Source: HSMN NewsFeed - July 21, 2021 Category: Pharmaceuticals Source Type: news
Creators call digital game prescription for ADHD the future of medicine. Critics call it a marketing ploy.
The FDA approved EndeavorRx for marketing. Developers say it can provide help for kids struggling in school and at home. But several ADHD experts say they’re overpromising.
Source: Washington Post: To Your Health - July 26, 2020 Category: Consumer Health News Authors: Katherine Ellison Source Type: news
Creators call digital game for ADHD children the future of medicine. Critics call it a marketing ploy.
The FDA approved EndeavorRx for marketing. Developers say it can provide help for kids struggling in school and at home. But several ADHD experts say they’re overpromising.
Source: Washington Post: To Your Health - July 26, 2020 Category: Consumer Health News Authors: Katherine Ellison Source Type: news
FDA Approves Video Game-Based Therapy for Kids With ADHD FDA Approves Video Game-Based Therapy for Kids With ADHD
The FDA granted marketing authorization for a digital game-based therapy that improves attention function in children with attention-deficit/hyperactivity disorder (ADHD).FDA Approvals
Source: Medscape Psychiatry Headlines - June 16, 2020 Category: Psychiatry Tags: Pediatrics News Alert Source Type: news
FDA Approves Video Game Made By Boston Company For Treating ADHD In Kids
BOSTON (AP) — The U.S. Food and Drug Administration has for the first time approved a video game for treating attention deficit hyperactivity disorder in children.
The FDA said Monday the game built by Boston-based Akili Interactive Labs can improve attention function.
The game, called EndeavorRx, requires a prescription and is designed for children ages 8 to 12 with certain symptoms of ADHD.
It’s the first time the FDA has cleared a digital therapy for improving ADHD symptoms, and the first time the agency has ever authorized marketing of a game-based therapy for any condition.
Screenshot of EndeavorRx (Photo cred...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 16, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston ADHD Children With ADHD EndeavorRx FDA Source Type: news
Teijin and NeuroSigma Enter into Exclusive License Agreement
Teijin Pharma to Market eTNS for the Treatment of ADHD in Japan
LOS ANGELES, Oct. 17, 2019 -- (Healthcare Sales & Marketing Network) -- Teijin Limited (Teijin) and NeuroSigma, Inc. (NeuroSigma), a Los Angeles-based bioelectronics company focused on dev... Devices, Neurology, Licensing NeuroSigma, Teijin, Trigeminal Nerve Stimulation, Monarch eTNS
Source: HSMN NewsFeed - October 17, 2019 Category: Pharmaceuticals Source Type: news
FDA permits marketing of first medical device for treatment of ADHD
The U.S. Food and Drug Administration permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (eTNS) System, is indicated for patients ages 7 to12 years old who are not currently taking prescription ADHD medication and is the first non-drug treatment for ADHD granted marketing authorization by the FDA.
Source: World Pharma News - April 23, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
FDA Clears First Device for Treating ADHD FDA Clears First Device for Treating ADHD
The US Food and Drug Administration has granted marketing authorization for the Monarch external trigeminal nerve stimulation system to treat ADHD in patients between the ages of 7 and 12 years.FDA Approvals
Source: Medscape Psychiatry Headlines - April 22, 2019 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news
FDA Approves Marketing of First Device to Treat ADHD
MONDAY, April 22, 2019 -- Marketing has been approved for the first medical device to treat attention-deficit/hyperactivity disorder (ADHD), the U.S. Food and Drug Administration announced Friday.
The Monarch external Trigeminal Nerve Stimulation...
Source: Drugs.com - Pharma News - April 22, 2019 Category: Pharmaceuticals Source Type: news
FDA permits marketing of first medical device for treatment of ADHD
Source: Food and Drug Administration - April 19, 2019 Category: American Health Source Type: news
When It Comes to Breastfeeding, This Is Why Women Never Feel Like They ’re Right
There may be nobody as vulnerable to manipulation as a mother worried about her child’s health. The question of whether we’re doing right by our kids cuts straight to the maternal heart. The problem is that in this age of marketing vs. activism, we’re overwhelmed and paralyzed by the debates about what’s best.
It’s not surprising, then, that there was an uproar when the New York Times reported on July 8 that the Trump Administration had tried to dilute a resolution at the World Health Assembly this spring that called on all nations to “protect, promote and support breastfeeding.” T...
Source: TIME: Health - July 12, 2018 Category: Consumer Health News Authors: Susanna Schrobsdorff Tags: Uncategorized breast milk breastfeeding Trump Administration WHO Source Type: news
Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments
KANSAS CITY, Kan., May 31, 2018 -- (Healthcare Sales & Marketing Network) -- Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delive... Biopharmaceuticals, Drug Delivery, Personnel Cingulate Therapeutics, Dexmethylphenidate, Dextroamphetamine, ADHD
Source: HSMN NewsFeed - May 31, 2018 Category: Pharmaceuticals Source Type: news
